Skip to main content

Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg

Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at U.S. regulators’ discretion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.